Latest News and Press Releases

ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally.

The IND approval marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform.

Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.

InnoCare remained profitable in the first quarter of 2026, with net profit increasing by 607.7% YoY to RMB 102.4 million.

ICP-B794 demonstrated potent anti-tumor activity in preclinical tumor models and a significantly larger safety window compared to similar drugs.

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual...

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced...

InnoCare’s next-generation TRK inhibitor Zurletrectinib receives priority review for the treatment of pediatric patients with solid tumors in China.

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.

The current indications of soficitinib under development are strategically positioned within the vast dermatology market.